

Republic of Moldova

Tuberculosis profile

Population 2015

4.1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.31 (0.3–0.33)	7.7 (7.3–8.1)
Mortality (HIV+TB only)	0.18 (0.11–0.27)	4.5 (2.8–6.6)
Incidence (includes HIV+TB)	6.2 (4–8.8)	152 (98–217)
Incidence (HIV+TB only)	0.55 (0.35–0.79)	13 (8.5–19)
Incidence (MDR/RR-TB)**	3.9 (2.9–4.8)	96 (71–118)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.17 (0.079–0.27)	1.5 (0.28–2.8)	1.7 (0.36–3.1)
Males	0.17 (0.1–0.25)	4.3 (3–5.6)	4.5 (3.1–5.8)
Total	0.35 (0.23–0.47)	5.8 (4.6–7.1)	6.2 (4–8.8)

TB case notifications, 2015	
Total cases notified	4 211
Total new and relapse	3 608
- % tested with rapid diagnostics at time of diagnosis	85%
- % with known HIV status	95%
- % pulmonary	90%
- % bacteriologically confirmed among pulmonary	64%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	58% (41–90)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.08 (0.05–0.13)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	300	9%
- on antiretroviral therapy	197	66%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 700 (1 600–1 800)
Estimated % of TB cases with MDR/RR-TB	32% (29–34)	69% (66–72)	
% notified tested for rifampicin resistance	56%	58%	2 390
MDR/RR-TB cases tested for resistance to second-line drugs			480
Laboratory-confirmed cases		MDR/RR-TB: 1 042, XDR-TB: 55	
Patients started on treatment ****		MDR/RR-TB: 1 020, XDR-TB: 48	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	79%	3 459
Previously treated cases, excluding relapse, registered in 2014	47%	292
HIV-positive TB cases, all types, registered in 2014	53%	241
MDR/RR-TB cases started on second-line treatment in 2013	57%	943
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically